Health Care • Industrial Specialties
$97.47 ▲ +1.08
(+1.12%)
MKT CAP: $18.59B • VOL: 2.04M
52W L $79 52W H $104
ZBH // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $8.23B | $7.68B | $7.39B |
| YoY Revenue Growth % | +7.2% | +3.8% | — |
| Gross Profit | $5.74B | $5.49B | $3.25B |
| Gross Margin % | 69.7% | 71.5% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $1.10B | $1.29B | $1.28B |
| Operating Margin % | 13.3% | 16.7% | 17.3% |
| Net Income (GAAP) | $705.1M | $903.8M | $1.02B |
| EBITDA (Normalized) | $1.28B | $1.45B | $1.54B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.70B | $1.50B | $1.58B |
| Capital Expenditures (CapEx) | $224.5M | $203.8M | $332.7M |
| Free Cash Flow (FCF) | $1.47B | $1.30B | $1.25B |
| FCF Margin % | 17.9% | 16.9% | 16.9% |
| Return on Invested Capital (ROIC %) | 4.6% | 5.9% | 16.3% |
| Cash & Short-Term Equivalents | $591.9M | $525.5M | $1.12B |
| Total Debt (Short + Long Term) | $6.93B | $5.34B | $2.39B |
| Total Stockholders' Equity | $12.70B | $12.47B | $4.91B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ZBH.